ArticleNeurology and therapy2026
Long-Term Impact of Cenobamate on Cognition, Adaptive Behavior, and Quality of Life in Patients with Tuberous Sclerosis Complex.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCenobamate is a recent therapeutic option for epilepsy, but few studies have investigated its impact on cognitive and emotional/behavioral functioning. The aim of our study was to assess cognitive function, adaptive behavior, quality of life, and parental stress in late adolescents and young adults with tuberous sclerosis complex (TSC) and drug-resistant epilepsy, treated with add-on cenobamate over a 12-month period using standardized neuropsychological tests.
methodsOur prospective observational study included 22 patients, aged 18 to 24 years with a diagnosis of TSC and drug-resistant epilepsy who started cenobamate add-on therapy for improving seizure control. At baseline and after 3- and 12-month follow-ups, participants completed a neuropsychological standardized assessment of executive functions (Epitrack©), adaptive behavior (VABS-II), quality of life (QOL), and parental stress (PSI). Cognitive functions (WAIS-IV) were reassessed only at the 12-month follow-up. Changes in standardized scores over time were analyzed using Friedman's two-way analysis of variance and post hoc analysis. Relationships between demographic/clinical variables and neuropsychological scores were analyzed using correlation analysis.
resultsOur study highlighted a statistically significant improvement in Epitrack, PSI-4-SF, and QOL scores after 3- or 12-month follow-ups (p < 0.05). Stability was maintained for the WAIS and VABS-II scores. The subjects with TSC2 mutations showed significantly lower IQ scores than those carrying TSC1 mutations (p < 0.001). Total parental stress (PSI) was significantly related to the total score of VABS-II at both baseline (p = 0.003) and 12 months (p = 0.001).
conclusionOur study suggested that cenobamate add-on therapy was effective and generally well tolerated in this cohort. Neuropsychological assessments suggest beneficial effects on executive functions, emotional well-being, social functioning, and quality of life. Furthermore, an improvement in parental stress also emerged. These findings could support clinicians in the decision-making process, evaluating cenobamate as an early treatment option in drug-resistant epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.